BACKGROUND:Soy isoflavones have antiestrogenic and anticancer properties but also possess estrogen-like properties, which has raised concern about soy food consumption among breast cancer survivors. OBJECTIVE: We prospectively evaluated the association between postdiagnosis soy food consumption and breast cancer outcomes among US and Chinese women by using data from the After Breast Cancer Pooling Project. DESIGN: The analysis included 9514 breast cancer survivors with a diagnosis of invasive breast cancer between 1991 and 2006 from 2 US cohorts and 1 Chinese cohort. Soy isoflavone intake (mg/d) was measured with validated food-frequency questionnaires. HRs and 95% CIs were estimated by using delayed-entry Cox regression models, adjusted for sociodemographic, clinical, and lifestyle factors. RESULTS: After a mean follow-up of 7.4 y, we identified 1171 total deaths (881 from breast cancer) and 1348 recurrences. Despite large differences in soy isoflavone intake by country, isoflavone consumption was inversely associated with recurrence among both US and Chinese women, regardless of whether data were analyzed separately by country or combined. No heterogeneity was observed. In the pooled analysis, consumption of ≥10 mg isoflavones/d was associated with a nonsignificant reduced risk of all-cause (HR: 0.87; 95% CI: 0.70, 1.10) and breast cancer-specific (HR: 0.83; 95% CI: 0.64, 1.07) mortality and a statistically significant reduced risk of recurrence (HR: 0.75; 95% CI: 0.61, 0.92). CONCLUSION: In this large study of combined data on US and Chinese women, postdiagnosis soy food consumption of ≥10 mg isoflavones/d was associated with a nonsignificant reduced risk of breast cancer-specific mortality and a statistically significant reduced risk of recurrence.
RCT Entities:
BACKGROUND: Soy isoflavones have antiestrogenic and anticancer properties but also possess estrogen-like properties, which has raised concern about soy food consumption among breast cancer survivors. OBJECTIVE: We prospectively evaluated the association between postdiagnosis soy food consumption and breast cancer outcomes among US and Chinese women by using data from the After Breast Cancer Pooling Project. DESIGN: The analysis included 9514 breast cancer survivors with a diagnosis of invasive breast cancer between 1991 and 2006 from 2 US cohorts and 1 Chinese cohort. Soy isoflavone intake (mg/d) was measured with validated food-frequency questionnaires. HRs and 95% CIs were estimated by using delayed-entry Cox regression models, adjusted for sociodemographic, clinical, and lifestyle factors. RESULTS: After a mean follow-up of 7.4 y, we identified 1171 total deaths (881 from breast cancer) and 1348 recurrences. Despite large differences in soy isoflavone intake by country, isoflavone consumption was inversely associated with recurrence among both US and Chinese women, regardless of whether data were analyzed separately by country or combined. No heterogeneity was observed. In the pooled analysis, consumption of ≥10 mg isoflavones/d was associated with a nonsignificant reduced risk of all-cause (HR: 0.87; 95% CI: 0.70, 1.10) and breast cancer-specific (HR: 0.83; 95% CI: 0.64, 1.07) mortality and a statistically significant reduced risk of recurrence (HR: 0.75; 95% CI: 0.61, 0.92). CONCLUSION: In this large study of combined data on US and Chinese women, postdiagnosis soy food consumption of ≥10 mg isoflavones/d was associated with a nonsignificant reduced risk of breast cancer-specific mortality and a statistically significant reduced risk of recurrence.
Authors: M E Martínez; J R Marshall; E Graver; R C Whitacre; K Woolf; C Ritenbaugh; D S Alberts Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-10 Impact factor: 4.254
Authors: Young H Ju; Daniel R Doerge; Kimberly F Allred; Clinton D Allred; William G Helferich Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: P L Horn-Ross; S Barnes; M Lee; L Coward; J E Mandel; J Koo; E M John; M Smith Journal: Cancer Causes Control Date: 2000-04 Impact factor: 2.506
Authors: Cynthia A Thomson; Anna Giuliano; Cheryl L Rock; Cheryl K Ritenbaugh; Shirley W Flatt; Susan Faerber; Vicky Newman; Bette Caan; Ellen Graver; Vern Hartz; Robin Whitacre; Felicia Parker; John P Pierce; James R Marshall Journal: Am J Epidemiol Date: 2003-04-15 Impact factor: 4.897
Authors: John P Pierce; Susan Faerber; Fred A Wright; Cheryl L Rock; Vicky Newman; Shirley W Flatt; Sheila Kealey; Vicky E Jones; Bette J Caan; Ellen B Gold; Mary Haan; Kathryn A Hollenbach; Lovell Jones; James R Marshall; Cheryl Ritenbaugh; Marcia L Stefanick; Cynthia Thomson; Linda Wasserman; Loki Natarajan; Ronald G Thomas; Elizabeth A Gilpin Journal: Control Clin Trials Date: 2002-12
Authors: Fang Fang Zhang; Danielle E Haslam; Mary Beth Terry; Julia A Knight; Irene L Andrulis; Mary B Daly; Saundra S Buys; Esther M John Journal: Cancer Date: 2017-03-06 Impact factor: 6.860
Authors: Xiyuan Zhang; Katherine L Cook; Anni Warri; Idalia M Cruz; Mariana Rosim; Jeffrey Riskin; William Helferich; Daniel Doerge; Robert Clarke; Leena Hilakivi-Clarke Journal: Clin Cancer Res Date: 2017-02-01 Impact factor: 12.531
Authors: Shannon M Conroy; Gertraud Maskarinec; Song-Yi Park; Lynne R Wilkens; Brian E Henderson; Laurence N Kolonel Journal: Nutr Cancer Date: 2013 Impact factor: 2.900